2

Overestimated treatment effects in randomised phase II trials: What's up doctor?

*European Journal of Cancer* 2019; 123:116-127

MX 2 is a novel regulator of cell cycle in melanoma cells

*Pigment Cell & Melanoma Research* 2019; 33(3):446-457

Marked variation in heritability estimates of left ventricular mass depending on modality of measurement

*Scientific Reports* 2019; 9:13556

Association of serum ustekinumab levels with clinical response in psoriasis

*JAMA Dermatology* 2019; 155(11):1235–1243

Transcriptomic analysis reveals prognostic molecular signatures of stage I melanoma

*Clinical Cancer Research* 2019; 25(24):7424-7435

Two-stage adaptive designs for three-treatment bioequivalence studies

*Statistics in Biopharmaceutical Research* 2019; 11(4):360-374

Body mass index (BMI), BMI change, and overall survival in patients with SCLC and NSCLC: A pooled analysis of the International Lung Cancer Consortium

*Journal of Thoracic Oncology* 2019; 14(9):1594-1607

To add or not to add a new treatment arm to a multiarm study: A decision-theoretic framework

*Statistics in Medicine* 2019; 38(18):3305-3321

The impact of an epilepsy nurse competency framework on the costs of supporting adults with epilepsy and intellectual disability: Findings from the EpAID study

*Journal of Intellectual Disability Research* 2019; 63(12):1391-1400

Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: A randomised controlled proof-of-concept trial

*ERJ Open Research* 2019; 5(3):00110-2019